Free Trial
LON:ERGO

Ergomed (ERGO) Share Price, News & Analysis

GBX 1,346
0.00 (0.00%)
(As of 11/13/2023)
Today's Range
1,346
1,346
50-Day Range
1,346
1,346
52-Week Range
895
1,380
Volume
280,999 shs
Average Volume
346,578 shs
Market Capitalization
£701.00 million
P/E Ratio
4,641.38
Dividend Yield
N/A
Price Target
GBX 1,400
ERGO stock logo

About Ergomed Stock (LON:ERGO)

Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally. The company operates through two segments, Clinical Research Services and Pharmacovigilance. It provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies. The company focuses on various therapeutic areas, including oncology, hematology, allergy, respiratory, and neurology/CNS, as well as develops orphan drugs. It also provides site support services. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.

ERGO Stock Price History

ERGO Stock News Headlines

Icon PLC IJF
Green Mining Innovation: Neuer Chief Financing Officer
Kiss of death from Joe Biden
As you’ll discover, behind closed doors in D.C. the elites have manufactured a shocking new economic and social crisis that threatens everything. Elon Musk calls it “staggering.”
Green Mining Innovation: New Chief Financing Officer
Invesco Ltd: Form 8.3 - Ergomed PLC
Kiss of death from Joe Biden
As you’ll discover, behind closed doors in D.C. the elites have manufactured a shocking new economic and social crisis that threatens everything. Elon Musk calls it “staggering.”
Man Group PLC : Form 8.3 - Ergomed plc
Form 8.3 - Ergomed_PLC
Samson Rock Capital LLP - Form 8.3 - Ergomed Plc
Form 8.3 - ERGO LN
See More Headlines
Receive ERGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ergomed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/18/2017
Today
7/23/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
1,400
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 1,400
High Stock Price Target
GBX 1,450
Low Stock Price Target
GBX 1,350
Potential Upside/Downside
+4.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
£15 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£152.09 million
Cash Flow
GBX 24.62 per share
Book Value
GBX 179 per share

Miscellaneous

Free Float
N/A
Market Cap
£701.00 million
Optionable
Not Optionable
Beta
0.79
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. Miroslav Reljanovic (Age 64)
    Founder & Executive Chairman
    Comp: $964.3k
  • Mr. Michael William Spiteri (Age 62)
    Chief Transformation & Technology Officer
    Comp: $52.77k
  • Jonathan Andrew Curtain (Age 47)
    CFO & Executive Director
  • Dr. Michael Forstner
    Head of Risk Management & Pharmacoepidemiology
  • Ms. Sally Amanuel
    President of PrimeVigilance
  • Dr. Gordana Tonkovic
    President of Clinical Research
  • Ms. Ronel Steyn
    Senior Vice President of Global Development
  • Keith Byrne
    Senior Vice-President of Capital Markets & Strategy
  • Joanne Bletcher
    Company Secretary

ERGO Stock Analysis - Frequently Asked Questions

How have ERGO shares performed this year?

Ergomed's stock was trading at GBX 1,346 at the beginning of the year. Since then, ERGO shares have increased by 0.0% and is now trading at GBX 1,346.
View the best growth stocks for 2024 here
.

How were Ergomed's earnings last quarter?

Ergomed plc (LON:ERGO) posted its earnings results on Monday, September, 18th. The company reported $1.20 earnings per share for the quarter. The firm earned $22.91 million during the quarter. Ergomed had a trailing twelve-month return on equity of 18.08% and a net margin of 9.87%.

How do I buy shares of Ergomed?

Shares of ERGO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Ergomed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ergomed investors own include Dicerna Pharmaceuticals (DRNA), AbbVie (ABBV), Axsome Therapeutics (AXSM), FuelCell Energy (FCEL), NIO (NIO), Science Applications International (SAIC) and Northern Dynasty Minerals (NAK).

This page (LON:ERGO) was last updated on 7/23/2024 by MarketBeat.com Staff

From Our Partners